Related Experiment Videos
Droperidol for acute migraine headache.
P B Richman1, U Reischel, A Ostrow
1Department of Emergency Medicine, Morristown Memorial Hospital, NJ 07962, USA.
The American Journal of Emergency Medicine
|August 19, 1999
Summary
Intramuscular droperidol effectively treated acute migraine headaches in an emergency department pilot study. This promising therapy provided symptomatic relief for 81% of patients with minimal side effects.
Area of Science:
- Emergency Medicine
- Neurology
- Pharmacology
Background:
- Acute migraine headache is a common emergency department (ED) presentation.
- Limited research exists on intramuscular droperidol for acute migraine management in the ED setting.
Purpose of the Study:
- To evaluate the efficacy and safety of intramuscular droperidol for acute migraine headache treatment in an ED.
- To assess symptomatic relief and adverse reactions within 30 minutes of administration.
Main Methods:
- Retrospective case series of 37 patients treated with 2.5 mg intramuscular droperidol for migraine.
- Data collected on demographics, prior analgesic use, and clinical progress at 30 minutes post-administration (t30).
- Primary outcome: symptomatic relief allowing discharge without further intervention.
Main Results:
- 81% (30/37) of patients achieved symptomatic relief at t30.
- 2 patients (5%) required rescue medication, and 5 (14%) experienced no relief.
- Observed adverse reactions included drowsiness (14%) and mild akathisia (8%).
Conclusions:
- Intramuscular droperidol appears to be a safe and effective option for acute migraine management in the emergency department.
- Further randomized, controlled trials are recommended to confirm these preliminary findings.